B. Balasa

发表

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

F. Zhan, B. Barlogie, J. Shaughnessy, 2008, Clinical Cancer Research.

CS 1 , a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

F. Zhan, B. Barlogie, J. Shaughnessy, 2008 .

CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice.

R. Tisch, H. Mcdevitt, N. Sarvetnick, 1997, Journal of immunology.

Coxsackieviral-mediated diabetes: induction requires antigen-presenting cells and is accompanied by phagocytosis of beta cells.

N. Sarvetnick, M. Horwitz, A. Ilic, 2004, Clinical immunology.

Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection.

N. Sarvetnick, B. Boehm, W. Karges, 2001, Clinical immunology.

The microbial product lipopolysaccharide confers diabetogenic potential on the T cell repertoire of BDC2.5/NOD mice: implications for the etiology of autoimmune diabetes.

N. Sarvetnick, B. Balasa, K. van Gunst, 2000, Clinical immunology.

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®

R. R. Robinson, J. Sheridan, A. Thakur, 2016, mAbs.

IL-10 impacts autoimmune diabetes via a CD8+ T cell pathway circumventing the requirement for CD4+ T and B lymphocytes.

N. Sarvetnick, B. Yeung, A. Good, 1998, Journal of immunology.

Mapping of thyroglobulin epitopes: Presentation of a 9mer pathogenic peptide by different mouse MHC class II isotypes

G. Carayanniotis, B. Balasa, V. Rao, 2005, Immunogenetics.

Interferon γ (IFN-γ) Is Necessary for the Genesis of Acetylcholine Receptor–induced Clinical Experimental Autoimmune Myasthenia gravis in Mice

P. Christadoss, N. Sarvetnick, L. Bradley, 1997, The Journal of experimental medicine.

Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse.

N. Sarvetnick, J. Davies, B. Balasa, 1999, Journal of immunology.

A Mechanism for IL-10-Mediated Diabetes in the Nonobese Diabetic (NOD) Mouse: ICAM-1 Deficiency Blocks Accelerated Diabetes1 2

N. Sarvetnick, A. La Cava, D. Balakrishna, 2000, The Journal of Immunology.

IL-10 deficiency does not inhibit insulitis and accelerates cyclophosphamide-induced diabetes in the nonobese diabetic mouse.

N. Sarvetnick, J. Katz, B. Balasa, 2000, Cellular immunology.

Autoimmune Myasthenia Gravis the Progression of Antibody-Dependent The Th 2 Cytokine IL-4 Is Not Required for and

P. Christadoss, N. Sarvetnick, C. Deng, 1998 .

Islet-Specific Expression of IL-10 Promotes Diabetes in Nonobese Diabetic Mice Independent of Fas, Perforin, TNF Receptor-1, and TNF Receptor-2 Molecules1

N. Sarvetnick, T. Hanafusa, D. Balakrishna, 2000, The Journal of Immunology.

Receptor-1 , and TNF Receptor-2 Molecules Independent of Fas , Perforin , TNF Diabetes in Nonobese Diabetic Mice Islet-Specific Expression of IL-10 Promotes

N. Sarvetnick, T. Hanafusa, D. Balakrishna, 2000 .

Is pathogenic humoral autoimmunity a Th1 response? Lessons from (for) myasthenia gravis.

N. Sarvetnick, B. Balasa, Nora Sarvetnick, 2000, Immunology today.

Diabetes in the Nonobese Diabetic Mouse IL-10-Mediated Acceleration of Autoimmune H-2D End Confers Dominant Protection from

B. Balasa, 2001 .

CCR2 and CCR5 chemokine receptors differentially influence the development of autoimmune diabetes in the NOD mouse

N. Sarvetnick, B. Balasa, Michelle F Solomon, 2010, Autoimmunity.

Differential impact of T cell repertoire diversity in diabetes-prone or -resistant IL-10 transgenic mice.

N. Sarvetnick, J. Lee, B. Balasa, 1999, Cellular immunology.

The paradoxical effects of interleukin 10 in the immunoregulation of autoimmune diabetes.

N. Sarvetnick, B. Balasa, 1996, Journal of autoimmunity.

H-2D End Confers Dominant Protection from IL-10-Mediated Acceleration of Autoimmune Diabetes in the Nonobese Diabetic Mouse1

N. Sarvetnick, A. La Cava, A. Good, 2001, The Journal of Immunology.

Induction of experimental autoimmune thyroiditis in rats with the synthetic peptide (2495-2511) of thyroglobulin.

G. Carayanniotis, B. Balasa, 1993, Cellular immunology.

Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse

F. Shi, N. Sarvetnick, J. Strominger, 2001, Proceedings of the National Academy of Sciences of the United States of America.

CS1: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma.

E. Hsi, V. Vexler, A. Draksharapu, 2006 .

Cytokines and IDDM: implications for etiology and therapy.

N. Sarvetnick, B. Balasa, 1998, Drug news & perspectives.

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

F. Zhan, B. Barlogie, J. Shaughnessy, 2009, Molecular Cancer Therapeutics.

CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody.

B. Barlogie, J. Shaughnessy, G. Tricot, 2006 .

The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.

P. Christadoss, N. Sarvetnick, J. Lee, 1998, Journal of immunology.

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

Michael D. Robbins, D. Chao, G. Starling, 2014, Cancer Immunology, Immunotherapy.

Interferon γ (IFN-γ) Is Necessary for the Genesis of Acetylcholine Receptor–induced Clinical Experimental Autoimmune Myasthenia gravis in Mice

P. Christadoss, N. Sarvetnick, L. Bradley, 1997, The Journal of experimental medicine.

The effect of elotuzumab on natural killer (NK) cell function against multiple myeloma (MM).

H. Kwon, D. Benson, G. Starling, 2011, Journal of Clinical Oncology.

Effect of Elotuzumab on Circulating Lymphocytes, Chemokines, and Cytokines In Multiple Myeloma Patients

J. Sheridan, Yuni Fang, A. Rice, 2010 .